Good evening - Over the last few months, biotech stocks have been moving up and down as the world digests every crumb of news about the progress towards a Covid-19 vaccine. But it’s time to face reality. There may not be the October surprise predicted by President Trump. Even the furthest vaccines down the road will likely only be completing late-stage trials by the end of October. After that, there has to be a waiting period to test for side effects. In short, it’s important to get this right. And that’s the way it should be. Operation Warp Speed was never about shortcutting science. It was geared to speeding up production when a vaccine is available. But that doesn’t mean 2021 will be a year-long version of Groundhog’s Day. If there’s anything that President Trump’s treatment has shown investors, it’s that biotech companies may be further down the road towards producing proven antiviral therapies for the novel coronavirus. Leaving the political issues aside, when experimental therapeutics are used (for now) successfully on a 74-year old, overweight man, that’s news. While it’s far too early to say whether these drugs truly carry the answer, it does confirm what some have suspected from the beginning of the pandemic. That is that therapeutics, rather than a vaccine, maybe the ultimate solution to the coronavirus puzzle. And as you might expect, dozens of companies are developing therapeutic treatments to mitigate the symptoms of infected patients. In this special presentation, we’re highlighting seven companies that you should be paying close attention to. If therapeutics nudge ahead of a vaccine, these stocks are likely to make strong upward moves. View the “7 Stocks That May Provide the Real Solution to the Coronavirus Puzzle”
Matthew Paulson
MarketBeat.com | 
No comments:
Post a Comment